N@N

Joel Beatty Initiated (ACAD) at Buy and Held Target at $40 on, Jan 30th, 2024

Joel Beatty of Baird, Initiated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $40 on, Jan 30th, 2024.

Joel has made no other calls on ACAD in the last 4 months.

There are 12 other peers that have a rating on ACAD. Out of the 12 peers that are also analyzing ACAD, 2 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $27 on, Monday, December 18th, 2023
• Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023

These are the ratings of the 10 analyists that currently disagree with Joel

---

• Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
• Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $40 on, Friday, December 29th, 2023
• Jeffrey Hung of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $40 on, Tuesday, December 19th, 2023
• Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $42 on, Thursday, December 14th, 2023
• David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $38 on, Wednesday, December 13th, 2023
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, November 6th, 2023
• Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $33 on, Friday, November 3rd, 2023
• Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $42 on, Friday, November 3rd, 2023
• Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $33 on, Tuesday, October 17th, 2023
• Tessa Romero of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $32 on, Tuesday, October 10th, 2023

Contributing Sources

---